[go: up one dir, main page]

JP2002516659A - 肺癌の治療および診断のための化合物、およびそれらの使用方法 - Google Patents

肺癌の治療および診断のための化合物、およびそれらの使用方法

Info

Publication number
JP2002516659A
JP2002516659A JP2000529432A JP2000529432A JP2002516659A JP 2002516659 A JP2002516659 A JP 2002516659A JP 2000529432 A JP2000529432 A JP 2000529432A JP 2000529432 A JP2000529432 A JP 2000529432A JP 2002516659 A JP2002516659 A JP 2002516659A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
patient
sequence
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000529432A
Other languages
English (en)
Japanese (ja)
Inventor
スティーブン ジー． リード，
マイケル ジェイ． ロデス，
トニー エヌ． フルダキス，
ラオドー モハマス，
Original Assignee
コリクサ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コリクサ コーポレイション filed Critical コリクサ コーポレイション
Publication of JP2002516659A publication Critical patent/JP2002516659A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2000529432A 1998-01-28 1999-01-26 肺癌の治療および診断のための化合物、およびそれらの使用方法 Withdrawn JP2002516659A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US1502298A 1998-01-28 1998-01-28
US1502998A 1998-01-28 1998-01-28
US09/015,029 1998-01-28
US09/015,022 1998-01-28
US4083198A 1998-03-18 1998-03-18
US4082898A 1998-03-18 1998-03-18
US09/040,831 1998-03-18
US09/040,828 1998-03-18
US12219198A 1998-07-23 1998-07-23
US12219298A 1998-07-23 1998-07-23
US09/122,192 1998-07-23
US09/122,191 1998-07-23
US21924598A 1998-12-22 1998-12-22
US09/219,245 1998-12-22
PCT/US1999/001642 WO1999038973A2 (fr) 1998-01-28 1999-01-26 Composes destines au diagnostic et a la therapie du cancer du poumon et procedes d'utilisation associes

Publications (1)

Publication Number Publication Date
JP2002516659A true JP2002516659A (ja) 2002-06-11

Family

ID=27567530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000529432A Withdrawn JP2002516659A (ja) 1998-01-28 1999-01-26 肺癌の治療および診断のための化合物、およびそれらの使用方法

Country Status (13)

Country Link
EP (1) EP1051489A2 (fr)
JP (1) JP2002516659A (fr)
KR (1) KR20010034436A (fr)
CN (1) CN1292029A (fr)
AR (1) AR014514A1 (fr)
AU (1) AU2344399A (fr)
BR (1) BR9907259A (fr)
CA (1) CA2319117A1 (fr)
ID (1) ID27813A (fr)
IL (1) IL137417A0 (fr)
NO (1) NO20003853L (fr)
WO (1) WO1999038973A2 (fr)
ZA (1) ZA99693B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521412A (ja) * 2004-11-30 2008-06-26 ベリデックス・エルエルシー 肺癌予後判定手段

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531315B1 (en) 1998-03-18 2003-03-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US6482597B1 (en) 1999-12-17 2002-11-19 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6960570B2 (en) 1998-03-18 2005-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6518256B1 (en) 1998-03-18 2003-02-11 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6660838B1 (en) 1998-03-18 2003-12-09 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US7049063B2 (en) 1998-03-18 2006-05-23 Corixa Corporation Methods for diagnosis of lung cancer
US6706262B1 (en) 1998-03-18 2004-03-16 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6737514B1 (en) 1998-12-22 2004-05-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6821518B1 (en) 1998-03-18 2004-11-23 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6426072B1 (en) 2000-08-02 2002-07-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6312695B1 (en) 1998-03-18 2001-11-06 Corixa Corporation Compounds and methods for therapy of lung cancer
US6696247B2 (en) 1998-03-18 2004-02-24 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
EP1526383A3 (fr) * 1998-08-31 2005-11-16 Pfizer Products Inc. Protéines de liaison pour diarylsulfonylurée
EP0987552A3 (fr) * 1998-08-31 2000-06-07 Pfizer Products Inc. Protéines de liaison pour diarylsulfonylurée
WO2000026241A2 (fr) * 1998-10-28 2000-05-11 Rigel Pharmaceuticals, Inc. Nouvelles compositions et nouveaux procedes pour identifier par criblage des modulateurs d'activation des lymphocytes t et des lymphocytes b
US6709855B1 (en) 1998-12-18 2004-03-23 Scios, Inc. Methods for detection and use of differentially expressed genes in disease states
EP1140137A2 (fr) * 1998-12-18 2001-10-10 Scios Inc. Methodes de detection et d'utilisation de genes exprimes de fa on differentielle dans des maladies
WO2000046370A1 (fr) * 1999-02-04 2000-08-10 Board Of Trustees Of The University Of Illinois Compositions p37ing1 et procedes d'utilisation
ES2202061T3 (es) 1999-02-19 2004-04-01 Zymogenetics, Inc. Inhibidores para usar en la funcion hemostatica e inmunologica.
US6544946B1 (en) 1999-02-19 2003-04-08 Zymogenetics, Inc. Inhibitors for use in hemostasis and immune function
ES2308976T3 (es) * 1999-04-02 2008-12-16 Corixa Corporation Compuestos y metodos para la terapia y el diagnostico del cancer de pulmon.
HK1045332A1 (zh) * 1999-04-02 2002-11-22 Corixa Corporation 用於治療和診斷肺癌的化合物及其使用方法
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6759508B2 (en) 2000-09-01 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6667154B1 (en) 1999-06-30 2003-12-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6686447B1 (en) 1999-06-30 2004-02-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6509448B2 (en) 1999-06-30 2003-01-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030125245A1 (en) 1999-06-30 2003-07-03 Tongtong Wang Compositions and methods for therapy and diagnosis of lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6914132B1 (en) 1999-06-30 2005-07-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6504010B1 (en) 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU769143B2 (en) 1999-06-30 2004-01-15 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6746846B1 (en) 1999-06-30 2004-06-08 Corixa Corporation Methods for diagnosing lung cancer
US6858204B2 (en) 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2309313A1 (fr) * 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation de la reponse immunitaire par manipulation des cellules dendritiques humaines
WO2001021653A2 (fr) * 1999-09-23 2001-03-29 Corixa Corporation Antigene de tumeur ovarienne et techniques d'utilisation de celui-ci
EP1669371A3 (fr) * 1999-12-01 2006-06-21 Genentech, Inc. Composition et procédés de diagnostic de tumeurs
JP2004518401A (ja) * 2000-04-14 2004-06-24 インサイト・ゲノミックス・インコーポレイテッド ヒトの生殖に関する分子
CA2414596A1 (fr) * 2000-06-29 2002-01-10 Corixa Corporation Compositions et methodes de diagnostic et de traitement du cancer des poumons
WO2002004514A2 (fr) * 2000-07-11 2002-01-17 Corixa Corporation Compositions et procedes pour le traitement et le diagnostic du cancer du poumon
AU2001270638A1 (en) * 2000-07-19 2002-01-30 Bayer Aktiengesellschaft Regulation of human airway trypsin protease-like enzyme
WO2002018562A1 (fr) * 2000-08-28 2002-03-07 Teijin Limited Enzymes de type trypsine propres aux voies respiratoires et leur procede d'utilisation
JP2005530479A (ja) 2001-01-16 2005-10-13 セローノ ジェネティクス インスティテュート ソシエテ アノニム 代謝遺伝子ポリヌクレオチドおよびポリペプチド並びにそれらの使用
GB0101300D0 (en) * 2001-01-18 2001-02-28 Univ Cambridge Tech Primordial germ cell genes
US7226994B2 (en) 2001-01-18 2007-06-05 Cambridge University Technical Services Limited Cell surface expressed marker of pluripotency
AU2002302851A1 (en) 2001-06-21 2003-01-08 Isis Innovations Limited Atopy
AU2003243151A1 (en) * 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
AU2007216892B2 (en) * 2002-08-16 2011-02-10 Agensys, Inc. Nucleic acids and corresponding proteins entitled 273P4B7 useful in treatment and detection of cancer
WO2004052917A2 (fr) * 2002-12-10 2004-06-24 Epimmune Inc. Peptides diriges contre des antigenes associes aux tumeurs hla-a1, a2 -a3,-a24,-b7,and -b44 et compositions
ES2542141T3 (es) 2005-10-17 2015-07-31 Sloan Kettering Institute For Cancer Research Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
WO2007120673A2 (fr) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Peptides wt1 immunogènes et leurs méthodes d'utilisation
US20100292090A1 (en) * 2006-08-25 2010-11-18 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
US20110236314A1 (en) * 2008-09-12 2011-09-29 Cancer Research Initiatives Foundation Method of detection and diagnosis of oral and nasopharyngeal cancers
CN101891802B (zh) * 2009-08-11 2011-11-16 武汉凯泰新生物技术有限公司 治疗或预防癌症的多肽或衍生产品及其应用
CN101921313B (zh) * 2010-04-07 2012-02-29 武汉凯泰新生物技术有限公司 治疗或预防癌症的多肽或其衍生产品及应用
GB201104286D0 (en) * 2011-03-15 2011-04-27 Randox Lab Ltd Glutathione S-transferase omega 1 wild type specific antibody
US9644026B2 (en) * 2011-09-09 2017-05-09 Trans Genic Inc. Antibody against mutant α-actinin-4
CN108676069A (zh) 2012-01-13 2018-10-19 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
SI2945647T1 (sl) 2013-01-15 2021-01-29 Memorial Sloan Kettering Cancer Center Imunogeni peptidi WT-1 in postopki za uporabo le-teh
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN115109120A (zh) * 2016-04-04 2022-09-27 英蒂分子公司 Cd8-特异性捕获剂、组合物及使用和制备方法
EP3541932A4 (fr) * 2016-11-16 2021-03-03 The Regents of the University of California Inhibiteurs de crispr-cas9
CN110669104B (zh) * 2019-10-30 2021-11-05 上海交通大学 一组来源于人外周血单核细胞的标志物及其应用
CN112500467B (zh) * 2020-12-14 2022-05-24 上海交通大学 一种生物活性肽rrecpsdecgagvf及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589579A (en) * 1994-07-19 1996-12-31 Cytoclonal Pharmaceutics, Inc. Gene sequence and probe for a marker of non-small cell lung carinoma
US5633161A (en) * 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521412A (ja) * 2004-11-30 2008-06-26 ベリデックス・エルエルシー 肺癌予後判定手段

Also Published As

Publication number Publication date
ID27813A (id) 2001-04-26
NO20003853L (no) 2000-09-27
CA2319117A1 (fr) 1999-08-05
IL137417A0 (en) 2001-07-24
EP1051489A2 (fr) 2000-11-15
WO1999038973A3 (fr) 1999-12-09
BR9907259A (pt) 2002-01-22
WO1999038973A2 (fr) 1999-08-05
NO20003853D0 (no) 2000-07-27
CN1292029A (zh) 2001-04-18
AR014514A1 (es) 2001-02-28
ZA99693B (en) 1999-10-21
KR20010034436A (ko) 2001-04-25
AU2344399A (en) 1999-08-16

Similar Documents

Publication Publication Date Title
JP2002516659A (ja) 肺癌の治療および診断のための化合物、およびそれらの使用方法
EP1064372B1 (fr) Composes et methodes therapeutiques et diagnostiques du cancer du poumon
US6887660B2 (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
EP2298877B1 (fr) Composés pour l'immunothérapie du cancer de la prostate et procédés pour leur utilisation
EP1992640A1 (fr) Composés pour l'immunothérapie et le diagnostic du cancer du sein et leurs procédés d'utilisation
JP2002533082A (ja) 結腸癌の免疫療法および診断のための化合物およびそれらの使用のための方法
JP2002532093A (ja) 卵巣癌の治療および診断のための組成物および方法
JP2002540790A (ja) 肺癌の治療および診断のための化合物ならびにその使用のための方法
EP1127893A2 (fr) Compositions thérapeutiques et diagnostiques du carcinome mammaire et méthodes afférentes
JP2010239970A (ja) 乳癌の処置および診断のための組成物ならびにそれらの使用方法
US6410507B1 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
US6387697B1 (en) Compositions for treatment and diagnosis of breast cancer and methods for their use
JP2002541803A (ja) 乳癌の処置および診断のための組成物ならびに方法
US20020111467A1 (en) Compositions and methods for the treatment and diagnosis of breast cancer
US6379951B1 (en) Compounds for immunotherapy of breast cancer and methods for their use
US7008772B1 (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
JP4942906B2 (ja) 卵巣癌の治療および診断のための組成物および方法
JP2009195236A (ja) 乳癌の免疫療法および診断のための化合物ならびにそれらの使用のための方法
US7270980B2 (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
EP2003201A2 (fr) Composés et méthodes thérapeutiques et diagnostiques du cancer du poumon
HK1105014A (en) Compounds and methods for therapy and diagnosis of lung cancer
HK1087737A (en) Compounds for immunodiagnosis of prostate cancer and method for their use
HK1037880A (en) Compositions and methods for the treatment and diagnosis of breast cancer

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20060404